Related references
Note: Only part of the references are listed.Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Dorothea Hose et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
BCMA-targeting approaches for treatment of multiple myeloma
Yunxin Chen et al.
PANMINERVA MEDICA (2021)
Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma
Marcin Jasinski et al.
FRONTIERS IN IMMUNOLOGY (2021)
Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Ignacio J. Cardona-Benavides et al.
CELLS (2021)
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
Massimo Offidani et al.
FRONTIERS IN ONCOLOGY (2021)
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Marc Braunstein et al.
EXPERT REVIEW OF HEMATOLOGY (2021)
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
Mattia D'Agostino et al.
LEUKEMIA (2020)
Early monoclonal protein decline pattern is an independent prognostic factor in patients with multiple myeloma
Limei Xu et al.
ANNALS OF HEMATOLOGY (2020)
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
Tiantian Ma et al.
ANNALS OF HEMATOLOGY (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson et al.
LANCET ONCOLOGY (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation
Seiichi Okabe et al.
ANNALS OF HEMATOLOGY (2019)
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Thomas G. Martin et al.
CELLS (2019)
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
Naoki Hosen
CANCERS (2019)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies
Chunrui Li et al.
BLOOD (2018)
Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Jacalyn Rosenblatt et al.
BLOOD (2017)
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
CARs in the Lead Against Multiple Myeloma
Maria Ormhoj et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Immunologic approaches for the treatment of multiple myeloma
Leo Rasche et al.
CANCER TREATMENT REVIEWS (2017)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
Tumor Load in Patients With Multiple Myeloma: β2-Microglobulin Levels Versus Whole-Body MRI
Melvin D'Anastasi et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Serum-free light-chain assay: clinical utility and limitations
Malini V. Bhole et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2014)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Share Paper
